(Q84396538)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

5 February 2020

main subject

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

F Sangalli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

L Moiola

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

S Bucello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A Rizzo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

M Radaelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

G Vitello

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

L M E Grimaldi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A Ghezzi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

V Martinelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

G Comi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

published in

Neurological Sciences

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

31 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

299-302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

5 February 2020

cites work

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20544247

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20544247

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20544247

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10072-010-0344-Z

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20544247%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference